ARVN - Company ID 0001655759
ARVINAS, INC. trades as ARVN. In its fiscal 2025 annual report the company posted revenue of $262.60M, down 0.3% from the prior year and net income of -$81.00M. This page tracks ARVINAS, INC. through 574 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
With latest filings
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Over the last 8 fiscal years ARVINAS, INC.'s revenue grew from $7.58M to $262.60M, a compound annual growth rate of 55.8%. Net profit margin expanded from -317.3% to -30.8% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Insider trade | 4 | 2026-05-22 |
| Insider sale notice | 144 | 2026-05-20 |
| Insider trade | 4 | 2026-05-13 |
| Insider trade | 4 | 2026-05-13 |
| Insider trade | 4 | 2026-05-13 |
| Insider trade | 4 | 2026-05-13 |
| Insider trade | 4 | 2026-05-13 |
| Major company event | 8-K | 2026-05-12 |
The largest companies sharing ARVINAS, INC.'s SEC industry classification (pharmaceutical preparations).
ARVINAS, INC. reported revenue of $262.60M for fiscal year 2025, a decrease of 0.3% year over year.
In its latest fiscal year ARVINAS, INC. reported a net loss of $81.00M.